2021 Partners

Natera_Logo

Natera

Lead Partner

Natera is a global leader in cell-free DNA (cfDNA) testing. The mission of the company is to change the management of disease worldwide with a focus on women's health, oncology and organ health. Developed by our trusted legacy in cfDNA, the Prospera transplant assessment test is optimized to be a precise and reliable tool for early, clinically meaningful rejection assessment. Renasight™ is a comprehensive, accessible renal genetics test for patients with chronic kidney disease. Learn more to help accelerate your research.

Discover More

Medpace_FullColor

Medpace

Innovation Partner

Medpace is a scientifically-driven, global, full service clinical contract research organization providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries; we have global experience conducting trials for a variety of kidney-related diseases from early through late phase. An international network of sites and strong relationships with KOLs streamlines the development process and is enhanced by our experience and history in recruiting hard to enroll patient populations. Our model embeds scientific expertise and guidance throughout your studies, providing greater depth and the ability to tackle complex and challenging diseases.

Discover More

MediBeacon-RM-2c

MediBeacon

Innovation Partner

MediBeacon is a medical technology company specializing in advances of fluorescent tracer agents and transdermal measurement with a focus on developing actionable point of care organ function measurements. MediBeacon technology is being shown to have many preclinical nephrology applications with over 275 peer-reviewed publications and conference abstracts in which Transdermal GFR (tGFR) has been used.

In 2018 the U.S. Food and Drug Administration granted Breakthrough Device designation to the Transdermal GFR Measurement System (TGFR). Clinical studies in subjects with normal and impaired kidney function are ongoing. Data readout of the TGFR Phase 3 Global Pivotal Study is expected in 2022.

Discover More